0QKL.L Stock Quote & Alerts

0QKL.L0QKL.L

No data available

Want to monitor 0QKL.L?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

No company information available

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

Key Statistics

About

News

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Stride

Allegiant to acquire Sun Country Airlines for $1.5B

Walmart's OnePay Employee Share Repurchase Hints at $4 Billion Valuation

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sprouts Farmers Market

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Zymeworks Outlines Strategic Priorities and Outlook for 2026

If You'd Invested $100 in Nvidia 10 Years Ago, Here's How Much You'd Have Today

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SLM Corporation

Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion

SoundHound AI: Buy or Sell in 2026?

StubHub Deadline: STUB Investors Have Opportunity to Lead StubHub Holdings, Inc. Securities Lawsuit

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

3 REITs Every Investor Should Know About

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results